Boston Scientific begins new WallFlex Biliary RX Stent study

Boston Scientific has announced the commencement of clinical investigation evaluating the use of the WallFlex Biliary RX Stent as a bridge to surgery among certain cancer patients.

The first patient has been enrolled for the new international trial, which will assess outcomes among patients treated with the self-expanding metal stent prior to surgical treatment for pancreatic or periampullary cancer, compared to the absence of biliary drainage.

Patients affected by these conditions often have high levels of bilirubin, which adversely affect their liver, cardiovascular and renal functions, but previous efforts to use plastic stents to address this issue have not proven successful.

It is hoped that WallFlex Biliary Stents – which are CE Marked for palliative treatment of biliary strictures produced by malignant neoplasms, as well as for use on benign biliary strictures – can provide a new solution.

David Pierce, president of endoscopy at Boston Scientific, said: "Boston Scientific is committed to advancing science through investment in robust clinical research, while delivering innovative technologies designed to improve quality of life for patients."

Earlier this month, the company reported study data showing the benefits its Watchman left atrial appendage closure device can offer in the treatment of atrial fibrillation.